TGF-β produced by CAFs excludes CD4 + and CD8 + T cells from entering the tumor [171] and an anti-TGF-β antibody could reverse tumor T cell exclusion and sensitize tumors to PD-L1 treatment [172]. Here, TGFB1 is linked to neoplasm.